Acadia Pharmaceuticals Inc. | Mid-cap | Healthcare

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 244.3M
Gross Profit 223.9M 91.65%
Operating Income 19.3M 7.90%
Net Income 19.0M 7.77%
EPS (Diluted) $0.11

Balance Sheet Metrics

Total Assets 1.1B
Total Liabilities 367.1M
Shareholders Equity 765.2M
Debt to Equity 0.48

Cash Flow Metrics

Operating Cash Flow 19.6M
Free Cash Flow -78.5M

Revenue & Profitability Trend

Acadia Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i957.8M726.4M517.2M484.1M441.8M
Cost of Goods Sold i81.8M41.6M10.2M19.1M20.6M
Gross Profit i876.0M684.8M507.1M465.0M421.2M
Gross Margin % i91.5%94.3%98.0%96.0%95.3%
Operating Expenses
Research & Development i303.2M351.6M361.6M239.4M319.1M
Selling, General & Administrative i488.4M406.6M369.1M396.0M388.7M
Other Operating Expenses i-----
Total Operating Expenses i791.7M758.2M730.7M635.4M707.8M
Operating Income i84.3M-73.4M-223.6M-170.4M-286.6M
Operating Margin % i8.8%-10.1%-43.2%-35.2%-64.9%
Non-Operating Items
Interest Income i25.5M17.2M6.6M591.0K6.6M
Interest Expense i-----
Other Non-Operating Income148.3M5.1M3.5M2.3M-997.0K
Pre-tax Income i258.1M-51.0M-213.4M-167.5M-281.0M
Income Tax i31.6M10.2M2.5M351.0K611.0K
Effective Tax Rate % i12.3%0.0%0.0%0.0%0.0%
Net Income i226.5M-61.3M-216.0M-167.9M-281.6M
Net Margin % i23.6%-8.4%-41.8%-34.7%-63.7%
Key Metrics
EBITDA i-46.4M-67.8M-221.6M-167.1M-283.7M
EPS (Basic) i$1.37$-0.37$-1.34$-1.05$-1.79
EPS (Diluted) i$1.36$-0.37$-1.34$-1.05$-1.79
Basic Shares Outstanding i165717000163819000161683000160493000157331000
Diluted Shares Outstanding i165717000163819000161683000160493000157331000

Income Statement Trend

Acadia Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i319.6M188.7M114.8M147.4M326.0M
Short-term Investments i436.4M250.2M302.0M373.3M305.9M
Accounts Receivable i98.7M98.3M62.2M64.4M48.2M
Inventory i21.9M35.8M6.6M7.9M9.7M
Other Current Assets-----
Total Current Assets i938.3M616.1M507.9M617.8M717.6M
Non-Current Assets
Property, Plant & Equipment i46.6M51.9M55.6M58.3M47.3M
Goodwill i119.8M65.5M001.1M
Intangible Assets i-----
Long-term Investments-----
Other Non-Current Assets78.9M10.9M18.3M16.0M7.4M
Total Non-Current Assets i249.4M132.8M79.9M82.3M65.0M
Total Assets i1.2B749.0M587.8M700.1M782.6M
Liabilities
Current Liabilities
Accounts Payable i16.2M17.5M12.7M6.9M8.5M
Short-term Debt i10.0M9.4M9.3M8.3M5.1M
Current Portion of Long-term Debt-----
Other Current Liabilities-----
Total Current Liabilities i394.9M254.3M125.6M96.1M106.0M
Non-Current Liabilities
Long-term Debt i42.0M47.8M52.7M56.1M44.5M
Deferred Tax Liabilities i-----
Other Non-Current Liabilities18.1M15.1M9.1M7.0M5.2M
Total Non-Current Liabilities i60.1M62.9M61.8M63.2M49.6M
Total Liabilities i455.0M317.2M187.4M159.2M155.6M
Equity
Common Stock i16.0K16.0K16.0K16.0K16.0K
Retained Earnings i-2.2B-2.4B-2.4B-2.2B-2.0B
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i732.8M431.8M400.4M540.9M627.0M
Key Metrics
Total Debt i52.0M57.2M62.0M64.4M49.5M
Working Capital i543.4M361.9M382.3M521.8M611.6M

Balance Sheet Composition

Acadia Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i226.5M-61.3M-216.0M-167.9M-281.6M
Depreciation & Amortization i15.9M5.6M2.0M3.3M2.9M
Stock-Based Compensation i67.0M66.4M68.2M63.6M84.4M
Working Capital Changes i-50.3M-57.3M11.2M-18.2M-4.4M
Operating Cash Flow i259.1M-46.7M-134.6M-119.1M-154.4M
Investing Activities
Capital Expenditures i-523.0K-50.0K0-1.1M-7.6M
Acquisitions i-----
Investment Purchases i-505.1M-370.0M-363.2M-492.8M-339.9M
Investment Sales i328.6M442.0M436.4M422.8M540.0M
Investing Cash Flow i-30.5M72.0M73.2M-71.1M192.5M
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i-----
Debt Repayment i-----
Financing Cash Flow i6.8M25.1M8.2M18.2M81.0M
Free Cash Flow i157.2M-23.3M-114.0M-126.8M-143.8M
Net Change in Cash i235.4M50.5M-53.1M-172.0M119.1M

Cash Flow Trend

Acadia Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 18.64
Forward P/E 30.23
Price to Book 5.08
Price to Sales 4.10
PEG Ratio -0.93

Profitability Ratios

Profit Margin 21.80%
Operating Margin 12.24%
Return on Equity 33.18%
Return on Assets 5.28%

Financial Health

Current Ratio 2.91
Debt to Equity 6.85
Beta 0.70

Per Share Data

EPS (TTM) $1.33
Book Value per Share $4.88
Revenue per Share $6.11

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
acad4.2B18.645.0833.18%21.80%6.85
Vertex 100.2B27.775.8322.77%31.86%8.89
Regeneron 62.9B14.952.0615.34%31.37%9.04
BridgeBio Pharma 9.4B-16.98-5.2436.76%98.25%-1.04
Madrigal 8.5B-17.6712.12-36.30%-54.68%17.81
Blueprint Medicines 8.4B-120.9924.43-47.71%-27.70%208.50

Financial data is updated regularly. All figures are in the company's reporting currency.